Ionis Pharmaceuticals (IONS) News Today $34.01 +0.07 (+0.21%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.65 Consensus PT from BrokeragesNovember 22 at 1:53 AM | americanbankingnews.comWhy Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?November 21 at 5:27 PM | finance.yahoo.comIonis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right NowNovember 20 at 7:58 PM | msn.comQualigen Therapeutics (NASDAQ:QLGN) & Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head ComparisonNovember 20 at 3:19 AM | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nineteen brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assNovember 19, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short InterestIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 10,740,000 shares, a growth of 8.8% from the October 15th total of 9,870,000 shares. Based on an average daily volume of 1,540,000 shares, the short-interest ratio is currently 7.0 days. Currently, 7.4% of the shares of the stock are short sold.November 18, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Lowered by StockNews.comNovember 16, 2024 | americanbankingnews.comIonis Pharmaceuticals price target lowered to $62 from $65 at Piper SandlerNovember 15, 2024 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low on Insider SellingIonis Pharmaceuticals (NASDAQ:IONS) Sets New 12-Month Low After Insider SellingNovember 15, 2024 | marketbeat.comEric Swayze Sells 1,194 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockNovember 15, 2024 | insidertrades.comPiper Sandler Has Lowered Expectations for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PricePiper Sandler lowered their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a report on Thursday.November 14, 2024 | marketbeat.comBaillie Gifford & Co. Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Baillie Gifford & Co. lessened its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 84.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,581 shares of the company's stock afterNovember 14, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Downgraded by StockNews.com to "Sell"StockNews.com downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for IONS FY2024 Earnings?Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. ForNovember 11, 2024 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for IONSIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities researchers at Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts thatNovember 8, 2024 | marketbeat.comARK Investment Management LLC Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)ARK Investment Management LLC raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 1.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,384,269 shares of the company's sNovember 8, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Gets a Hold from BarclaysNovember 8, 2024 | markets.businessinsider.comQ3 2024 Ionis Pharmaceuticals Inc Earnings CallNovember 8, 2024 | finance.yahoo.comStifel Nicolaus Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)November 7, 2024 | markets.businessinsider.comIonis Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Performance and Promising Future ProspectsNovember 7, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS)Needham & Company LLC reiterated a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday.November 7, 2024 | marketbeat.comIonis to present at upcoming investor conferencesNovember 7, 2024 | prnewswire.comIonis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comIonis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comIonis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman SyndromeNovember 6, 2024 | prnewswire.comIonis reports third quarter 2024 financial resultsNovember 6, 2024 | prnewswire.comIonis Announces FDA Acceptance Of NDA For Donidalorsen For Prophylactic Treatment Of HAENovember 5, 2024 | markets.businessinsider.comIonis Pharmaceuticals: FDA accepts for review NDA for donidalorsenNovember 5, 2024 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.comStockNews.com upgraded Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday.November 4, 2024 | marketbeat.comIonis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAENovember 4, 2024 | prnewswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by abrdn plcabrdn plc grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 22.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 303,274 shares of the company's stock after buying an additional 56,357 shareNovember 2, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 6.3% in OctoberIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 9,870,000 shares, a decline of 6.3% from the September 30th total of 10,530,000 shares. Currently, 6.8% of the shares of the stock are sold short. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is presently 6.3 days.October 31, 2024 | marketbeat.comInternational Assets Investment Management LLC Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)International Assets Investment Management LLC grew its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 3,287.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,772 shares of the company's stocOctober 31, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Set to Announce Quarterly Earnings on WednesdayIonis Pharmaceuticals (NASDAQ:IONS) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638986)October 30, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Rating Lowered to Sell at StockNews.comStockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday.October 25, 2024 | marketbeat.comIonis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory SuccessesOctober 25, 2024 | seekingalpha.comIonis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three yearsOctober 24, 2024 | finance.yahoo.comIonis to hold third quarter 2024 financial results webcastOctober 23, 2024 | prnewswire.comIonis Pharmaceuticals (IONS) Receives a Buy from TD CowenOctober 21, 2024 | markets.businessinsider.comWAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisOctober 21, 2024 | prnewswire.comQ3 2024 Earnings Forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Issued By Leerink PartnrsIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Leerink Partnrs raised their Q3 2024 EPS estimates for Ionis Pharmaceuticals in a report issued on Monday, October 14th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.91) for the quartOctober 17, 2024 | marketbeat.comSanctuary Advisors LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sanctuary Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,441 shares ofOctober 13, 2024 | marketbeat.comMillennium Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Millennium Management LLC trimmed its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 78.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,215 shares of the company's stock after selling 454,964October 11, 2024 | marketbeat.comDimensional Fund Advisors LP Decreases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Dimensional Fund Advisors LP reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 18.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 88,746 shares of the company's stock after selliOctober 10, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge FundsOctober 9, 2024 | msn.comIONS Factor-Based Stock AnalysisOctober 4, 2024 | nasdaq.comNew positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 3, 2024 | prnewswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Clearbridge Investments LLCClearbridge Investments LLC cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 51.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,160,270 shares of the company's stock after selling 2,305,921 shares during the perioOctober 3, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 52.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,210 shares of the company's stock afterOctober 2, 2024 | marketbeat.comIonis Gets FDA Fast-Track Designation for Zilganersen in Alexander DiseaseOctober 1, 2024 | marketwatch.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.090.49▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼77▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHVN News Today RARE News Today PRGO News Today JAZZ News Today BHC News Today ACAD News Today ARWR News Today UTHR News Today INCY News Today NBIX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
